Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Sage Chief Medical Officer Laura Gault, M.D., Ph.D., is stepping down to pursue a new opportunity effective March 21, the ...

马萨诸塞州剑桥市 - 市值4.49亿美元、专注于脑健康治疗的生物制药公司Sage Therapeutics, Inc. (NASDAQ: SAGE )今日宣布，其首席医疗官Laura Gault博士将离职寻求新的发展机会。她的离职将于2025年3月21日生效。Gault博士自2022年11月加入公司以来，一直负责监督公司的产品管线开发。根据 InvestingPro ...